Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...
Although the majority of patients are diagnosed with early-stage disease, outcomes remain poor for those with primary advanced or recurrent endometrial cancer, with reported 5-year survival rates as ...
About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--A new College of American Pathologists (CAP) evidence-based guideline is among the first to address testing based less on the cancer type or tumor origin and more on ...
Prevalence of BRCA1/2 mutations among an Irish cohort unrestricted by testing eligibility thresholds. Association of breast cancer risk in women of African ancestry with genetic variants in the ...
In today’s era of precision medicine, the management of most solid tumors is increasingly driven by biomarker testing, the results of which often drive treatment decisions. Perhaps the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results